Aytu BioPharma (NASDAQ:AYTU – Get Free Report) was downgraded by Maxim Group from a “buy” rating to a “hold” rating in a research report issued on Tuesday, Marketbeat.com reports.
A number of other equities analysts also recently issued reports on the company. Zacks Research downgraded Aytu BioPharma from a “hold” rating to a “strong sell” rating in a report on Monday, October 5th. Citigroup reaffirmed a “positive” rating on shares of Aytu BioPharma in a research report on Tuesday, September 22nd. Weiss Ratings downgraded shares of Aytu BioPharma from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, October 6th. Finally, Lake Street Capital lowered shares of Aytu BioPharma from a “buy” rating to a “hold” rating and set a $2.70 price target for the company. in a research note on Tuesday. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $8.60.
View Our Latest Stock Analysis on Aytu BioPharma
Aytu BioPharma Price Performance
Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last announced its earnings results on Monday, November 16th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.06. The firm had revenue of $14.84 million during the quarter, compared to analyst estimates of $13.27 million. Aytu BioPharma had a negative return on equity of 74.74% and a negative net margin of 34.34%. As a group, equities analysts forecast that Aytu BioPharma will post -0.16 earnings per share for the current year.
Hedge Funds Weigh In On Aytu BioPharma
Institutional investors and hedge funds have recently modified their holdings of the stock. Nantahala Capital Management LLC purchased a new position in shares of Aytu BioPharma in the 2nd quarter worth about $2,336,646. Stonepine Capital Management LLC bought a new position in Aytu BioPharma in the 2nd quarter worth about $1,962,780. AWM Investment Company Inc. purchased a new stake in Aytu BioPharma during the 2nd quarter valued at about $1,332,000. BlackRock Inc. purchased a new stake in Aytu BioPharma during the 2nd quarter valued at about $49,000. Finally, Crown Advisors Management Inc. purchased a new stake in Aytu BioPharma during the 2nd quarter valued at about $430,000. 33.49% of the stock is currently owned by institutional investors.
Top Aytu BioPharma Stories
Investors following AYTU have been watching these stories:
- Positive Sentiment: Rosemont agreed to acquire Aytu for $2.70 per share in cash, a reported 41.1% premium to the prior share price. The takeover announcement has been the main catalyst behind the recent sharp rally. If completed, the deal would take Aytu private; until closing, the offer remains subject to transaction completion. Inflexion’s Rosemont Pharmaceuticals agrees deal for Aytu BioPharma at 41.1 percent premium
- Neutral Sentiment: Maxim Group and Lake Street Capital downgraded AYTU from Buy to Hold; Lake Street’s $2.70 target is in line with the proposed cash offer, leaving the takeover price as a key reference point for investors.
- Negative Sentiment: Coverage of fiscal 2027 first-quarter results said Aytu swung to a loss amid higher costs, which may temper the positive deal news. Aytu BioPharma Swings To Q1 Loss On Higher Costs; Agrees To $56 Mln Buyout By Rosemont
About Aytu BioPharma
Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing prescription treatments. Its business has centered on medicines for attention-deficit/hyperactivity disorder (ADHD) and other pediatric conditions. The company’s product portfolio has included ADHD medications such as Adzenys XR-ODT, an orally disintegrating amphetamine tablet, and Cotempla XR-ODT, an extended-release methylphenidate tablet. Aytu has also marketed treatments for other pediatric needs, including allergies.
Further Reading
- Five stocks we like better than Aytu BioPharma
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
